Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX

Key Points

• Sanofi bought 2,708,559 shares of Immuneering for about $18.96 million in Q3, making IMRX its 5th largest holding (≈7.3% of Sanofi’s portfolio) and representing a 6.52% ownership stake in the company.
• Insiders have been buying stock recently — directors Peter Feinberg and Thomas Schall purchased 20,000 and 21,645 shares at ~$4.35 and ~$4.67 respectively, with insiders acquiring 51,819 shares (~$234k) in the past three months and now owning 22.90% of the company.
• Market and analyst view: IMRX trades around $4.63 (down 4.9%), market cap ≈ $299M, while analysts give a consensus “Moderate Buy” with an average price target of $16.50; the company is a clinical‑stage AI-driven biotech with lead program IRX‑2 in Phase 2.

Sanofi bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,708,559 shares of the company's stock, valued at approximately $18,960,000. Immuneering makes up approximately 7.3% of Sanofi's portfolio, making the stock its 5th largest position. Sanofi owned 6.52% of Immuneering at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Jane Street Group LLC purchased a new position in shares of Immuneering during the first quarter valued at about $32,000. Future Financial Wealth Managment LLC purchased a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Kingsview Wealth Management LLC bought a new stake in Immuneering in the 2nd quarter worth approximately $47,000. XTX Topco Ltd purchased a new stake in shares of Immuneering during the 2nd quarter worth approximately $90,000. Finally, Wendell David Associates Inc. purchased a new stake in Immuneering during the third quarter valued at $105,000. Hedge funds and other institutional investors own 67.65% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on IMRX shares. Chardan Capital restated a "buy" rating and set a $20.00 target price on shares of Immuneering in a research report on Thursday, November 13th. Leerink Partners initiated coverage on Immuneering in a research note on Friday, October 31st. They set an "outperform" rating and a $15.00 price objective on the stock. Wall Street Zen lowered shares of Immuneering from a "hold" rating to a "sell" rating in a research note on Saturday, December 20th. Mizuho set a $12.00 price target on shares of Immuneering in a report on Wednesday, October 29th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immuneering in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.50.

Insider Transactions at Immuneering

In other news, Director Peter Feinberg acquired 20,000 shares of Immuneering stock in a transaction dated Monday, January 12th. The stock was purchased at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the purchase, the director directly owned 135,441 shares in the company, valued at $589,168.35. This trade represents a 17.32% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas J. Schall bought 21,645 shares of the firm's stock in a transaction that occurred on Thursday, January 15th. The shares were purchased at an average cost of $4.67 per share, with a total value of $101,082.15. Following the acquisition, the director directly owned 74,530 shares of the company's stock, valued at approximately $348,055.10. This trade represents a 40.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 51,819 shares of company stock worth $234,472 over the last three months. Corporate insiders own 22.90% of the company's stock.

Immuneering Stock Down 4.9%

Shares of Immuneering stock opened at $4.63 on Friday. The company has a 50 day moving average price of $5.99 and a 200 day moving average price of $5.87. The firm has a market capitalization of $298.96 million, a P/E ratio of -2.60 and a beta of 0.48. Immuneering Corporation has a 52 week low of $1.10 and a 52 week high of $10.08.

Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). As a group, research analysts anticipate that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Immuneering Company Profile

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.